Epigenetic changes associated with Bacillus Calmette-Guerin (BCG) treatment in bladder cancer
- PMID: 38806074
- DOI: 10.1016/j.bbcan.2024.189123
Epigenetic changes associated with Bacillus Calmette-Guerin (BCG) treatment in bladder cancer
Abstract
Bacillus Calmette-Guérin (BCG) treatment for non-muscle invasive bladder cancer (NMIBC) is an established immunotherapeutic, however, a significant portion of patients do not respond to treatment. Despite extensive research into the therapeutic mechanism of BCG, gaps remain in our understanding. This review specifically focuses on the epigenomic contributions in the immune microenvironment, in the context of BCG treatment for NMIBC. We also summarise the current understanding of NMIBC epigenetic characteristics, and discuss how future targeted strategies for BCG therapy should incorporate epigenomic biomarkers in conjunction with genomic biomarkers.
Keywords: BCG; Bacillus Calmette-Guérin; Bladder cancer; Cancer; Cancer diagnostics; DNA methylation; Epigenetics; Immunology.
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical